Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
Jesus San-Miguel, Saad Z. Usmani, Maria Victoria Mateos, Niels W.C.J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Kevin Liu, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Andrew Farnsworth, Hareth Nahi, Ajai Chari
Research output: Contribution to journal › Article › peer-review
24Scopus
citations
Fingerprint
Dive into the research topics of 'Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)'. Together they form a unique fingerprint.